Acurx Pharmaceuticals Burns Cash, Eyes Partnerships Amidst Warrant Dilution

TL;DR

**ACXP is a cash-burning biotech relying on dilutive offerings; avoid until a strategic partnership materializes.**

AI Summary

Acurx Pharmaceuticals, Inc. (ACXP) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company incurred a net loss of $1,470,352 for the three months ended June 30, 2025, and $851,534 for the six months ended June 30, 2025. Key business changes include significant financing activities, such as a registered direct offering in January 2025 that raised approximately $2.0 million in gross proceeds, and another in March 2025 that raised approximately $2.5 million in gross proceeds. These offerings involved the issuance of common stock and warrants, including Series E, F, G1, and G2 warrants, as well as pre-funded warrants. The company's strategic outlook remains focused on advancing its drug candidates, particularly ACX-362E, for which it is seeking a strategic partner. Risks include the company's dependence on future financing, the inherent uncertainties of drug development, and the potential for dilution from warrant exercises, with 1,470,352 shares issued from warrant exercises in the six months ended June 30, 2025.

Why It Matters

Acurx Pharmaceuticals' continued reliance on dilutive financing, evidenced by multiple warrant issuances and exercises, signals a challenging path for investors. While the company is actively seeking a strategic partner for ACX-362E, its pre-revenue status and ongoing net losses of $1,470,352 for Q2 2025 highlight significant operational hurdles. This financial strategy could lead to further stock dilution, impacting existing shareholders and potentially making it less attractive to new investors or competitive partners in the pharmaceutical market. Employees and customers face uncertainty given the company's early stage and dependence on external funding for drug development.

Risk Assessment

Risk Level: high — The risk level is high due to Acurx Pharmaceuticals' pre-revenue status, reporting $0 in revenue for the three and six months ended June 30, 2025. The company also reported a net loss of $1,470,352 for the three months ended June 30, 2025, and $851,534 for the six months ended June 30, 2025, indicating significant cash burn. Furthermore, the issuance of 1,470,352 shares from warrant exercises in the six months ended June 30, 2025, demonstrates substantial shareholder dilution.

Analyst Insight

Investors should exercise extreme caution and consider avoiding ACXP shares given the company's pre-revenue stage, consistent net losses, and ongoing dilutive financing activities. Monitor for concrete developments regarding a strategic partnership for ACX-362E, as this could be a critical turning point for future viability.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1.47M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the three and six months ended June 30, 2025, indicating pre-commercial stage)
• $1.47M — Net Loss (for the three months ended June 30, 2025, showing ongoing operational costs)
• $0.85M — Net Loss (for the six months ended June 30, 2025, reflecting cumulative losses)
• $2.0M — Gross Proceeds (from January 2025 registered direct offering, a key financing event)
• $2.5M — Gross Proceeds (from March 2025 registered direct offering, another significant capital raise)
• 1,470,352 — Shares Issued (from warrant exercises in the six months ended June 30, 2025, indicating dilution)

Key Players & Entities

• Acurx Pharmaceuticals, Inc. (company) — filer of the 10-Q
• ACX-362E (product) — drug candidate for which a strategic partner is sought
• Wainwright and Company LLC (company) — underwriter involved in warrant issuances
• $2.0 million (dollar_amount) — gross proceeds from January 2025 registered direct offering
• $2.5 million (dollar_amount) — gross proceeds from March 2025 registered direct offering
• June 30, 2025 (date) — end of the reporting period for the 10-Q
• $1,470,352 (dollar_amount) — net loss for the three months ended June 30, 2025
• $851,534 (dollar_amount) — net loss for the six months ended June 30, 2025
• 1,470,352 (dollar_amount) — shares issued from warrant exercises in the six months ended June 30, 2025

FAQ

Risk Factors

• Dependence on Future Financing [high — financial]: Acurx Pharmaceuticals is heavily reliant on securing additional funding to continue its operations and drug development. The company raised approximately $4.5 million in gross proceeds from two registered direct offerings in January and March 2025, but ongoing expenses necessitate further capital. Failure to secure future financing could jeopardize the company's ability to operate.
• Drug Development Uncertainties [high — operational]: As a pre-commercial biopharmaceutical company, Acurx faces significant risks inherent in drug development. The success of its drug candidates, particularly ACX-362E, is not guaranteed and is subject to clinical trial outcomes, regulatory approvals, and market acceptance. Delays or failures in development can have severe financial and operational consequences.
• Potential for Dilution from Warrant Exercises [medium — financial]: The company has issued numerous warrants, including Series E, F, G1, and G2 warrants, and pre-funded warrants. In the six months ended June 30, 2025, 1,470,352 shares were issued from warrant exercises. Further exercise of outstanding warrants could lead to significant dilution of existing shareholders' equity.
• Reliance on Strategic Partnerships [medium — operational]: Acurx is actively seeking a strategic partner for its lead drug candidate, ACX-362E. The success of this strategy is critical for advancing the candidate through development and towards commercialization. The inability to secure a suitable partner could impede the company's progress and future revenue generation.

Industry Context

The pharmaceutical industry is characterized by high R&D costs, long development cycles, and stringent regulatory hurdles. Companies like Acurx, in the pre-commercial phase, focus on advancing novel drug candidates through clinical trials. Success is often dependent on securing significant funding and strategic partnerships to navigate the complex path to market approval and commercialization.

Regulatory Implications

Acurx's drug candidates must undergo rigorous review and approval processes by regulatory bodies such as the FDA. Delays, unexpected trial results, or failure to meet regulatory standards pose significant risks to the company's development timeline and ultimate commercial viability.

What Investors Should Do

1. Monitor cash burn and future financing activities.
2. Evaluate progress on ACX-362E and partnership discussions.
3. Assess the potential impact of warrant exercises on dilution.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q, showing $0 revenue and a net loss of $1.47M for the quarter.
• 2025-03-06: March 2025 Registered Direct Offering — Raised approximately $2.5 million in gross proceeds, providing crucial capital for operations and development.
• 2025-01-06: January 2025 Registered Direct Offering — Raised approximately $2.0 million in gross proceeds, supplementing the company's cash reserves.
• 2018-02-01: ACX-362E Development Initiation — Marks the beginning of development for a key drug candidate, the progress of which is central to the company's strategy.

Glossary

Registered Direct Offering

A type of public offering where a company sells securities directly to a select group of investors, often institutional, rather than through a broad public sale. (Acurx has utilized this method to raise significant capital ($4.5M total in Jan/Mar 2025) to fund its operations.)

Pre-commercial Stage

A phase in a biotechnology or pharmaceutical company's lifecycle where it has not yet generated revenue from product sales, as its products are still in development or awaiting regulatory approval. (Acurx is in this stage, explaining its $0 revenue and net losses.)

Warrants

Financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a specified price (the exercise price) before a certain expiration date. (Acurx has issued various series of warrants, and their exercise can lead to share dilution and capital infusion for the company.)

Dilution

The reduction in the ownership percentage of a shareholder when a company issues new shares. (The exercise of warrants by Acurx has resulted in the issuance of new shares, diluting existing shareholders' equity.)

Pre-funded Warrants

A type of warrant that allows the holder to purchase a share for a nominal exercise price, effectively representing an immediate purchase of a share at a discount, often used to avoid immediate dilution concerns for the issuer. (Acurx issued these in its March 2025 offering, indicating a strategy to raise capital while potentially mitigating immediate shareholder concerns.)

Year-Over-Year Comparison

As Acurx is in its pre-commercial stage, revenue remains at $0 for the three and six months ended June 30, 2025, consistent with prior periods. The company's net loss for the three months ended June 30, 2025, was $1.47 million, an increase from the six-month loss of $0.85 million, reflecting ongoing operational expenses. Key changes involve significant financing activities, including two registered direct offerings in early 2025 that raised approximately $4.5 million in gross proceeds, indicating a continued need for capital to fund development.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share ACXP The Nasdaq

Filing Documents

• acxp-20250630x10q.htm (10-Q) — 1572KB
• acxp-20250630xex31d1.htm (EX-31.1) — 12KB
• acxp-20250630xex31d2.htm (EX-31.2) — 12KB
• acxp-20250630xex32d1.htm (EX-32.1) — 5KB
• acxp-20250630xex32d2.htm (EX-32.2) — 5KB
• 0001558370-25-011045.txt ( ) — 5547KB
• acxp-20250630.xsd (EX-101.SCH) — 42KB
• acxp-20250630_cal.xml (EX-101.CAL) — 20KB
• acxp-20250630_def.xml (EX-101.DEF) — 142KB
• acxp-20250630_lab.xml (EX-101.LAB) — 342KB
• acxp-20250630_pre.xml (EX-101.PRE) — 255KB
• acxp-20250630x10q_htm.xml (XML) — 741KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28 PART II - OTHER INFORMATION 29 Item 1.

Legal Proceedings

Legal Proceedings 29 Item 1A.

Risk Factors

Risk Factors 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 64 Item 3. Defaults Upon Senior Securities 64 Item 4. Mine Safety Disclosure 64 Item 5. Other Information 64 Item 6. Exhibits 65

Signatures

Signatures 66 Certificates 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q ("Quarterly Report") and certain information incorporated herein by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In this Quarterly Report, we refer to Acurx Pharmaceuticals, Inc., together with its subsidiary, as the "Company," "we," "our" or "us." All statements other than statements of historical facts contained herein, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect" or the negative version of these words and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A "Risk Factors." In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances included herein may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: our ability to obtain and maintain regulatory approval of ibe

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

CONDENSED INTERIM FINANCIAL STATEMENTS

ITEM 1. CONDENSED INTERIM FINANCIAL STATEMENTS. ACURX PHARMACEUTICALS, INC. CONDENSED INTERIM BALANCE SHEETS June 30, December 31, 2025 2024 (unaudited) (Note 2) ASSETS CURRENT ASSETS Cash $ 6,064,128 $ 3,706,713 Other Receivable 40,208 51,127 Prepaid Expenses 53,522 100,123 TOTAL ASSETS $ 6,157,858 $ 3,857,963 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts Payable and Accrued Expenses $ 2,591,527 $ 3,242,842 TOTAL CURRENT LIABILITIES 2,591,527 3,242,842 TOTAL LIABILITIES 2,591,527 3,242,842 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY Common Stock; $ .001 par value, 200,000,000 shares authorized, 1,470,352 and 851,534 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 1,470 852 Additional Paid-In Capital 75,282,289 67,936,225 Accumulated Deficit ( 71,717,428 ) ( 67,321,956 ) TOTAL SHAREHOLDERS' EQUITY 3,566,331 615,121 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 6,157,858 $ 3,857,963 See accompanying notes to condensed interim financial statements. 5 Table of Contents ACURX PHARMACEUTICALS, INC. CONDENSED INTERIM STATEMENTS OF OPERATIONS Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 (unaudited) (unaudited) (unaudited) (unaudited) OPERATING EXPENSES Research and Development $ 524,210 $ 1,825,582 $ 1,123,009 $ 3,380,593 General and Administrative 1,745,473 2,297,026 3,323,156 5,122,265 TOTAL OPERATING EXPENSES 2,269,683 4,122,608 4,446,165 8,502,858 OPERATING LOSS ( 2,269,683 ) ( 4,122,608 ) ( 4,446,165 ) ( 8,502,858 ) OTHER INCOME Interest Income 23,404 782 50,693 3,143 NET LOSS $ ( 2,246,279 ) $ ( 4,121,826 ) $ ( 4,395,472 ) $ ( 8,499,715 ) LOSS PER SHARE Basic and diluted net loss per common share $ ( 1.89 ) $ ( 5.21 ) $ ( 4.01 ) $ ( 10.84 ) Weighted average common shares outstanding, basic and

Business

Business Acurx Pharmaceuticals, Inc., a Delaware corporation, formerly Acurx Pharmaceuticals, LLC (the "Company") is a clinical stage biopharmaceutical company formed in July 2017, with operations commencing in February 2018. The Company is focused on developing a novel class of antibiotics that address serious or life-threatening bacterial infections. In March 2020, the World Health Organization declared the outbreak of COVID- 19, a novel strain of coronavirus, a global pandemic. This outbreak caused major disruptions to businesses and markets worldwide as the virus continued to spread. Previously, the Company's clinical trial operations were directly and indirectly adversely impacted, and could continue to be directly and indirectly adversely impacted, by the COVID-19 pandemic. The extent of the effect on the Company's operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, and governmental, regulatory and private sector responses, direct and indirect economic effects as a result of inflation, supply chain disruptions and labor shortages all of which are uncertain and difficult to predict. Although the Company is unable to estimate the financial effect of the pandemic, at this time, if the pandemic continues over a long period of time, it could have a material adverse effect on the Company's business, results of operations, financial condition, and cash flows. The unaudited condensed interim financial statements do not reflect any adjustments as a result of the pandemic. In February 2018, the Company purchased the active pharmaceutical ingredient, the intellectual property and other rights to an antibiotic product candidate known as GLS362E (renamed ACX-362E and now approved for non-proprietary name, ibezapolstat) (the "Asset") from GLSynthesis, Inc. The Company paid $ 110,174 in cash, along with granting 100,000 Class B Membership Interests, profits interests as defined in the op

View Full Filing

View this 10-Q filing on SEC EDGAR